Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This platform trial will evaluate various immunotherapy combinations given in the
neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal
adenocarcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)